This is a non-material policy engagement with zero financial data, no FDA interaction, and no new funding. Traders should view it as a routine press release with no near-term catalyst. Monitor for actual clinical trial results or partnership announcements instead.
Price Chart
Executive Summary
Clearmind Medicine submitted a formal response to the HHS RFI on addiction treatment innovations as part of the Great American Recovery Initiative, highlighting its non-hallucinogenic neuroplastogen candidate CMND-100 (MEAI) for Alcohol Use Disorder. This is a routine regulatory submission with no new clinical data, funding, or partnership — purely a policy engagement with forward-looking statements.
Key Facts
- Clearmind submitted a formal response to the U.S. HHS RFI about MEAI's potential as an intervention for addiction treatment under the Great American Recovery Initiative.
- The filing highlights its proprietary MEAI-based candidate CMND-100 for AUD and binge behaviors, emphasizing non-hallucinogenic, at-home scalability.
- No new clinical data, funding, partnership, or regulatory milestone was announced — the company simply responded to a government request for information.
Financial Impact
No financial terms or material commitments disclosed; purely a policy submission.
Risk Factors
- No new funding or revenue source — the company remains a clinical-stage biotech with extremely small market cap and high cash burn risk.
- The filing is entirely forward-looking; regulatory submissions of this type do not guarantee any change in treatment access, funding, or FDA approval pathway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-077122 |
| Document: ea0297625-6k_clearmind.htm | 0001213900-26-077122 |
| Document: 0001213900-26-077122-index-headers.html | 0001213900-26-077122 |
| Document: 0001213900-26-077122-index.html | 0001213900-26-077122 |
| Document: 0001213900-26-077122.txt | 0001213900-26-077122 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.80%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.06%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.97 (+532.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers